Lilly Update on Supply Chain Reliability and Position on Stockpiling

Among the concerns raised due to the novel coronavirus is whether patients can count on a reliable supply of medicine. Lilly does not currently anticipate shortages for any of our medicines, including all forms of insulin. Lilly is committed to medicines that meet safety, quality, value and environmental expectations. With the help of a large network of global external manufacturing partners we supply medicine to nearly 125 countries. Lilly has an absolute commitment to public health and the needs of people with chronic conditions who depend on our medicines across the globe.

Since the initial outbreak, Lilly has closely monitored our supply chain for potential impact to our medicines around the world. Our insulin manufacturing sites in the U.S. and Europe have not been materially impacted, and Lilly does not source active pharmaceutical ingredients (API) for any of our approved medicines from China. We’ve taken several actions to protect our manufacturing processes, such as allowing only manufacturing and R&D employees into our facilities.

Globally, our manufacturing network is operational and taking steps to prevent impact. We’re also in close communication with key suppliers regarding supplies of raw materials. As the global situation evolves, we will continue to take the steps necessary to safeguard the reliable supply of our medicines.

Lilly has a global monitoring system that allows us to be in the best position to determine the necessary supply of medicines to meet our obligation to patients and health care providers in each country. For that reason, we will not honor requests to stockpile or hoard our medications, whether for profit or due to a sense of concern. Unnecessary stockpiling of medication can create unintended shortages and puts other patients’ health at risk. We will consider emergency requests on a case by case basis, and we have created a special rapid response unit for expedited consideration of these requests.

Lilly insulin and other medicines are available in U.S. pharmacies. Pharmacies that don’t have certain medicines in stock can order them from wholesalers, with delivery in 1-2 days. If you or a family member have an acute need, Lilly can help you obtain an emergency supply of insulin at no cost. In the U.S., you can dial the Lilly Diabetes Solution Center at (833) 808-1234. For other medicines, you can contact the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979). If you have any concerns about your medicines or if you are sick at home and in need of medicine, call or visit your health care professional.

This release contains forward-looking statements regarding Lilly’s efforts regarding the novel coronavirus. These statements are based on management’s current expectations, but actual results may differ materially. Other risk factors that may affect the company’s results can be found in the company’s latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.